https://www.selleckchem.com/products/asn007.html Existing measures of sexual functioning in prostate cancer survivors focus primarily on erectile function and do not adequately measure the experiences of sexual minority men. To develop and psychometrically evaluate a new scale to measure sexual functioning among sexual minority men with prostate cancer. Sexual minority prostate cancer patients (n=401) completed an online battery of urinary and sexual functioning tests in 2019, including a new 37-item instrument about their sexual functioning post-treatment for prostate cancer. We used confirmatory factor analysis to determine the construct validity of a new scale including five subscales a four-factor model for all participants (n=401) evaluated Sexual Satisfaction, Sexual Confidence, Frequency of Sexual Problems, and Urinary Incontinence in Sex. A single-factor model completed only by participants who had attempted or desired receptive anal sex (n=255) was evaluated in the fifth subscale Problematic Receptive Anal Sex. To evaluate criterion validitlidation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study. J Sex Med 2022;19529-540. In previous work, we engaged key stakeholders to create a web-based decision aid (DA) prototype to facilitate shared decision making about hypospadias. The study's objective was to use a human-centered design approach to assess the DA's acceptability and usability and revise it prior to pilot testing. We recruited English-speaking parents (≥18 years old) of sons with hypospadias (≤5 years) for a two-phase process of semi-structured phone/video interviews to obtain feedback about our DA prototype. DA webpages included "Hypospadias," "Surgery Basics," "No Surgery," "Family Stories," "Help Me Decide," and "FAQs." In both phases, participants viewed the DA using the "think aloud" technique and completed several validated scales to evaluate its acceptability and usability. In phase 1, w